NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
28.12 -0.17 (-0.62%)
As of 3:33 PM EDT. Market Open.
Loading Chart for PFE
DELL
  • Previous Close 28.30
  • Open 28.48
  • Bid 28.24 x 3000
  • Ask 28.25 x 3100
  • Day's Range 28.12 - 28.54
  • 52 Week Range 25.20 - 31.54
  • Volume 26,197,328
  • Avg. Volume 30,616,875
  • Market Cap (intraday) 159.376B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 37.50
  • EPS (TTM) 0.75
  • Earnings Date Jan 28, 2025 - Feb 3, 2025
  • Forward Dividend & Yield 1.68 (5.94%)
  • Ex-Dividend Date Nov 8, 2024
  • 1y Target Est 33.15

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Related Videos: PFE

Pfizer CEO on company's 'exceptional quarter' & Starboard fight

After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market Domination to discuss the "exceptional quarter." Bourla notes that Pfizer in addition to earnings and revenue, the company's COVID and non-COVID businesses also topped expectations. He tells Yahoo Finance, "When you have a quarter like that, really you feel that you are in a good way of executing what you said you will do." While there have been questions about the sustainability of Pfizer's COVID business, Bourla explains, "It's clear to me that the COVID business has stabilized into the new levels that will be the sustainable levels for the future. We are having already a second year of repetition." As Pfizer continues its proxy battle with activist investor Starboard Value, Bourla says that he agrees with some of the points made, like poor shareholder returns. However, he disagrees with "a lot" of other points, like spending and acquisitions, and calls the Pfizer-BioNTech (BNTX) deal "transformational." He notes that Starboard Value CEO Jeff Smith has said that there are many changes that need to be made in the company. However, he believes that he has already addressed the main issues: "I changed everything 12 months ago. Let me repeat what we did as changes. We changed our commercial model with new leaders and US international separated. We have delivered three consecutive quarters of growth... We announced a $4 billion cut in SI&A (selling, informational, and administrative) and OpEx (operational expenditures)." Bourla also points to leadership changes and new board members as initiatives to create new shareholder value. He argues that these efforts have been working and has led the company to perform "very well." To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Melanie Riehl

Performance Overview: PFE

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
2.08%
S&P 500
20.22%

1-Year Return

PFE
2.54%
S&P 500
36.74%

3-Year Return

PFE
26.85%
S&P 500
24.52%

5-Year Return

PFE
4.85%
S&P 500
88.78%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

Annual
As of 10/31/2024
  • Market Cap

    160.37B

  • Enterprise Value

    221.94B

  • Trailing P/E

    37.73

  • Forward P/E

    9.50

  • PEG Ratio (5yr expected)

    0.75

  • Price/Sales (ttm)

    2.66

  • Price/Book (mrq)

    1.83

  • Enterprise Value/Revenue

    3.69

  • Enterprise Value/EBITDA

    18.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.16%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    59.38B

  • Net Income Avi to Common (ttm)

    4.27B

  • Diluted EPS (ttm)

    0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.1B

  • Total Debt/Equity (mrq)

    79.41%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: PFE

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 17.7B
Earnings 4.46B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

27.00
33.15 Average
28.12 Current
45.00 High
 

Company Insights: PFE

Research Reports: PFE

View More
  • Daily – Vickers Top Buyers & Sellers for 11/01/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • COVID products drive 3Q24 beat on EPS

    Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.

    Rating
    Price Target
     
  • Throughout 2024, the stock market has remained in a solid uptrend that has

    Throughout 2024, the stock market has remained in a solid uptrend that has lifted most styles and sizes. With three trading days remaining in October, the S&P 500 was up 22.1% year to date on a capital-appreciation basis. The Nasdaq, which lagged the broad market index for most of the year, is now ahead with a 23.7% gain. And the blue-chip DJIA is up 12.5%, with its deep lag attributable mainly to struggling component stocks including Boeing, Intel, and Nike While the S&P 500's rise across 2024 has been punctuated by some selling jags, the index mainly has been in climbing mode. The S&P's trading year 2024 started with a run from the 4,740s level on January 1 to around 5,250 by the end of March. After a down April, the index climbed from the 5,020s on 5/1/24 to the 5,670s by mid-July. The index made a low in the 5,180s early in August and a higher low around 5,400 early in September. The index mainly has risen since then, hitting its all-time closing high in the 5,860s on 10/18/24. The index has remained above its 50-day simple moving average (SMA) for nearly the entire year; and dips below that trendline have been remarkably short. The index first broke its 50-day SMA on 4/12/24 but was back above the intermediate-term trendline about three weeks later on 5/3/24. The next breach in the 50-day SMA occurred in the 5,520s on 7/31/24 and lasted two weeks until 8/14/24. The lower high from mid-August could not hold, and the 50-day again failed at the higher low from early September. In this case, the 50-day breach lasted less than a week, from 9/4/24 to 9/10/24. Even with some mid-October churn, the S&P 500 currently has a 140-point cushion over its 50-day SMA.

     
  • Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     

Top Analysts: PFE

View More

Overall Score

Cantor Fitzgerald 47/100
Latest Rating
Overweight
 

Direction Score

BMO Capital 42/100
Latest Rating
Outperform
 

Price Score

Truist Securities 100/100
Latest Rating
Buy
 

People Also Watch